Table.1 The Descriptive summary of global landscape of malaria sporozoite challenge studies conducted from 1990 to 2018
Characteristics | Number of studies |
|---|---|
Sporozoite challenge study based on purpose | |
 Sporozoite infectivity studies | 19 |
 Malaria vaccine efficacy studies | 44 |
 Drug evaluation (chemoprophylaxis) | 5 |
 Acquired immunity assessment | 2 |
Country trial conducted | |
 USA | 31 |
 Netherlands | 11 |
 UK | 9 |
 Germany | 3 |
 Colombia | 5 |
 Spain | 2 |
 Tanzania | 2 |
 Kenya | 3 |
 Gabon | 1 |
 Equatorial Guinea | 1 |
 Mali | 2 |
Allocation to treatment | |
 Randomized placebo-controlled | 39 |
 Non-randomized controlled | 16 |
 Open-label | 2 |
 Not known | 9 |
Masking type | |
 Double-blind | 26 |
 Single-blind | 6 |
 Open-label | 35 |
 Not known | 3 |
Intervention model | |
 Parallel assignment | 54 |
 Single group assignment | 8 |
 Factorial assignment | 2 |
 Not known | 5 |
Phase of study | |
 Phase 1 | 32 |
 Phase 1/2a | 20 |
 Phase 2 | 6 |
 Not applicable | 6 |
 Not known | 5 |
Sporozoite challenge study type | |
 Mosquito bite based | 52 |
 PfSPZ challenge based | 18 |
Strain/clone of plasmodium used | |
 PfNF54 | 29 |
 Pf3D7 | 24 |
 PfNF166.C8 | 3 |
 PfNF135.C10 | 3 |
 Pf7G8 | 4 |
 Pv clinical isolate | 7 |
Mosquito species used | |
 A.stephensi | 44 |
 A.albimanus | 5 |
 A. gambiae | 1 |
 A.dirus | 1 |